Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 · New England Journal of Medicine · 3,852 citations
https://doi.org/10.1056/nejmoa050516
J
Jewel Johanns
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
149
Papers
16.3K
Citations
37
h-index
52
i10-index
Jewel Johanns is an academic researcher from Johnson & Johnson (United States). The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Immunodeficiency and Autoimmune Disorders. The author has an h-index of 37, co-authored 127 publications.
Papers by this author
worksUstekinumab as Induction and Maintenance Therapy for Crohn’s Disease
2016 · New England Journal of Medicine · 1,764 citations
https://doi.org/10.1056/nejmoa1602773
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
2019 · New England Journal of Medicine · 1,130 citations
https://doi.org/10.1056/nejmoa1900750
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012 · New England Journal of Medicine · 1,116 citations
https://doi.org/10.1056/nejmoa1203572
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2013 · Gastroenterology · 912 citations
https://doi.org/10.1053/j.gastro.2013.05.048
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008 · Gastroenterology · 740 citations
https://doi.org/10.1053/j.gastro.2008.07.014
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat